Eli Lilly and Company (Lilly) said that tirzepatide has shown superior efficacy over placebo in chronic weight management, according to the results from the phase 3 clinical trial SURMOUNT-2. Tested on patients with obesity or overweight and type 2 diabetes, the trial reported that tirzepatide, at doses of 10 mg and 15 mg, led to […]
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 billion. BAQSIMI is indicated for the treatment of severe hypoglycemia, which is very low blood sugar, in people with diabetes aged four years and over. It is the first as […]
Eli Lilly and Company (Lilly) has been granted fast track designation for tirzepatide from the US Food and Drug Administration (FDA) for the treatment of adults having obesity, or are overweight with weight-associated comorbidities. Tirzepatide is a weekly once glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The American pharma giant said […]